Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centessa Pharmaceuticals plc filings document the regulatory record of a clinical-stage pharmaceutical issuer with American Depositary Shares listed on Nasdaq, each representing one ordinary share. Disclosures cover its orexin receptor 2 (OX2R) agonist focus, operating and financial results, corporate presentations, risk and capital-structure matters, and securities registered in connection with the ADS program.
Centessa's SEC filings also include Form 8-K material-event reports for underwriting and at-the-market sales agreements, public offerings of ADSs, executive and board changes, employment and advisory arrangements, and Regulation FD materials. Proxy filings describe governance, shareholder voting matters, compensation topics, and related public-company controls.
FMR LLC files Amendment No. 4 to a Schedule 13G/A reporting ownership of 1,800 shares of Centessa Pharmaceuticals plc common stock. The filing lists the CUSIP 152309100, shows 1,800 shares beneficially owned representing 0.0% of the class, and names Abigail P. Johnson in the cover responses. Signatures are dated 07/07/2026.
Farallon Capital Management and related reporting persons have fully exited their position in Centessa Pharmaceuticals plc. In this Amendment No. 1 to their Schedule 13D, they report beneficial ownership of 0 ordinary shares and 0% of the class. The change reflects their disposal of all previously reported Centessa ordinary shares on June 24, 2026, in connection with the closing of Eli Lilly and Company’s acquisition of all outstanding Centessa ordinary shares through its wholly owned subsidiary LDH XV Corporation, as described in Centessa’s Form 8-K.
Farallon Capital Management and related individuals report beneficial ownership of 9,370,093 Centessa Pharmaceuticals ordinary shares, equal to 6.1% of the class based on 154,731,309 shares outstanding as of June 10, 2026. The stake, held through several Farallon investment partnerships via American Depositary Shares, reflects an approximate aggregate investment cost of $325,995,909. The group describes Centessa as an attractive investment and may buy more shares, sell, hedge, or take other actions over time to maximize the value of its position, while stating it has no specific corporate-change plans beyond what is outlined in the filing.
Medicxi Ventures Management (Jersey) Ltd reported open-market sale transactions in this Form 4 filing.
Centessa Pharmaceuticals plc disclosed that investment entities affiliated with Medicxi completed the transfer of a total of 19,963,157 Ordinary Shares in connection with the acquisition of Centessa by Eli Lilly and Company. The transfer occurred automatically at the effective time of a UK Scheme of Arrangement, not through discretionary open-market trading by the reporting entities.
Under the deal, each Ordinary Share (and each ADS representing one Ordinary Share) entitled holders to receive $38.00 in cash per share, plus one non-transferable contingent value right for potential additional payments of up to $9.00 per share upon achievement of specified milestones. Following these transactions, the reported Medicxi-related holdings of Centessa Ordinary Shares decreased to zero, and the reporting persons note they disclaim beneficial ownership except to the extent of any pecuniary interest.
INDEX VENTURES LIFE VI (JERSEY) L.P. reported open-market sale transactions in this Form 4 filing.
Centessa Pharmaceuticals plc reported that investment entities associated with Index Ventures completed the transfer of 9,961,789 Ordinary Shares in connection with the company’s acquisition by Eli Lilly and Company. The shares, held indirectly through Index Ventures Life VI (Jersey) L.P. and Yucca (Jersey) SLP, moved automatically at the effective time of a UK Scheme of Arrangement, rather than through a discretionary market trade.
At the effective time, each Ordinary Share became entitled to receive $38.00 in cash per share, plus one non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. The reporting persons disclaim beneficial ownership of these securities except to the extent of any pecuniary interest.
Centessa Pharmaceuticals’ Chief Legal Officer, Iqbal J. Hussain, reported the automatic disposition of his equity in connection with Eli Lilly’s acquisition of Centessa. On June 24, 2026, all of his Ordinary Shares and share options, including 5,500 shares held indirectly by his spouse and 117,645 shares held directly, were transferred pursuant to a court-approved scheme of arrangement.
At the effective time, each Ordinary Share (and each ADS representing one Ordinary Share) became entitled to receive $38.00 in cash plus one non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. His unvested RSUs, covering 98,025 Ordinary Shares, fully vested and, along with all outstanding options, were cancelled and converted into the same cash-and-CVR package rather than being exercised.
Centessa Pharmaceuticals plc Chief Technology & Quality Officer Tia L. Bush reported the automatic disposition of her equity in connection with Eli Lilly and Company’s acquisition of all outstanding Centessa ordinary shares. Bush’s 147,954 Ordinary Shares and all reported share options were transferred to the acquirer under a UK scheme of arrangement, leaving her with zero directly held shares and options after the transactions.
At the effective time of the scheme, holders of Ordinary Shares became entitled to receive $38.00 in cash per share, less applicable taxes, plus one non-transferable contingent value right (CVR) for each share. Each CVR provides for potential contingent payments of up to an aggregate of $9.00 per share, subject to specified milestones. The same per-share terms apply to American Depositary Shares, each representing one Ordinary Share. Unvested restricted share units fully vested and, along with share options, were cancelled and converted into the right to receive the cash consideration and one CVR per underlying Ordinary Share.
Centessa Pharmaceuticals plc Chief Financial Officer John J. Crowley reported dispositions of his equity in connection with the acquisition of Centessa by Eli Lilly and Company. On June 24, 2026, Eli Lilly, through a subsidiary, acquired all outstanding Centessa Ordinary Shares via a UK scheme of arrangement.
At the effective time, holders of Ordinary Shares became entitled to receive $38.00 in cash per Ordinary Share plus one contingent value right (CVR) for potential additional payments of up to $9.00 per Ordinary Share. The same terms applied per American Depositary Share.
Crowley disposed of 45,000 Ordinary Shares and had his Restricted Share Units and share options automatically cancelled and converted into rights to receive the cash consideration and one CVR per underlying share. The footnotes state these transfers occurred automatically under the Transaction Agreement, without any action or discretion by Crowley.
Centessa Pharmaceuticals’ Chief People Officer Karen M. Anderson reported the automatic disposition of all her equity in connection with Eli Lilly’s acquisition of the company. On the effective date of the UK court-approved scheme of arrangement, all her 62,085 Ordinary Shares transferred to Lilly.
Each Ordinary Share entitled the holder to receive $38.00 in cash plus a non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. Unvested RSUs covering 58,050 Ordinary Shares fully vested and were similarly cancelled for cash and CVRs.
All outstanding share options held by Anderson, including grants over 117,000, 120,000, 83,924, 28,336 and 75,000 Ordinary Shares at various exercise prices, were cancelled and converted into cash equal to the excess of the $38.00 cash consideration over each option’s exercise price, plus one CVR per underlying share. Following these transactions, she reported no remaining Ordinary Shares or options.